Company Encyclopedia
View More
name
Dermata Therapeutics
DRMA.US
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc.
1.912 T
DRMA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

    Dermata Therapeutics, Inc. announced plans to unveil a new brand identity for its OTC skincare line, emphasizing science-driven dermatologic innovation. The brand aims to redefine skincare by combining ancestral wisdom with scientific innovation, targeting consumers who demand better science and results. The new identity will be revealed soon, with the first OTC acne kit launching in mid-2026. Forward-looking statements caution about risks and uncertainties in product development and commercialization.

    Acceswire·
    US
    DRMA
    -1.83%
    Acceswire·
    US
    DRMA
    -1.83%

    Dermata Therapeutics: Strategic Shift and Financial Stability Support Buy Rating

    Analyst Anthony Vendetti from Maxim Group maintains a Buy rating on Dermata Therapeutics, with a $10.00 price target. Dermata plans to launch an OTC acne treatment kit in 2026, leveraging Spongilla technology. The strategic shift reduces market time and regulatory hurdles. Dermata has $4.7 million cash, no debt, and aims for broader e-commerce expansion by 2027. Despite being pre-revenue, Vendetti is confident in Dermata's future prospects.

    Tip Ranks·
    US
    DRMA
    -1.83%
    Tip Ranks·
    US
    DRMA
    -1.83%

    Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million

    Dermata Therapeutics Inc :DERMATA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING

    Reuters·
    US
    DRMA
    -1.83%
    Reuters·
    US
    DRMA
    -1.83%

    Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing

    Dermata Therapeutics Inc :DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILINGDERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATE

    Reuters·
    US
    DRMA
    -1.83%
    Reuters·
    US
    DRMA
    -1.83%

    Dermata Therapeutics Shifts Focus to OTC Skincare

    Dermata Therapeutics announced a strategic shift from prescription dermatology products to over-the-counter (OTC) skincare solutions, with plans to launch a once-weekly acne kit in mid-2026. This move aims to leverage their scientific expertise and Spongilla technology to meet consumer demand and enhance market position. The most recent analyst rating on DRMA stock is a Buy with a $10.00 price target, though TipRanks’ AI Analyst rates it as Underperform due to financial health concerns and bearish technical analysis.

    Tip Ranks·
    US
    DRMA
    -1.83%
    Tip Ranks·
    US
    DRMA
    -1.83%
    © 2025 Longbridge｜Disclaimer